<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987987</url>
  </required_header>
  <id_info>
    <org_study_id>P040441</org_study_id>
    <nct_id>NCT00987987</nct_id>
  </id_info>
  <brief_title>Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion</brief_title>
  <acronym>ILD-Treg</acronym>
  <official_title>Amplifying Graft-versus-tumor Effect by Donor Regulatory T-cell Depletion Before Donor Lymphocytes Infusion: a Phase I/II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Paris XII</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have previously shown that depletion of CD4+CD25+FoxP3+ regulatory T cells
      (Treg) enhances the alloreactivity of T lymphocytes, as attested by an accelerated GVHD after
      allogeneic hematopoietic stem cell transplantation (HSCT) in mice. The investigators thus
      propose a clinical trial to test whether Treg-depleted donor lymphocytes infusion (dDLI)
      could induce an improved graft-versus-tumor (GVT) effect in patients refractory to standard
      DLI (stdDLI) for treatment of relapse after HSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have previously shown that depletion of CD4+CD25+FoxP3+ regulatory T cells (Treg) enhances
      the alloreactivity of T lymphocytes, as attested by an accelerated GVHD after allogeneic
      hematopoietic stem cell transplantation (HSCT) in mice. We thus propose a clinical trial to
      test whether Treg-depleted donor lymphocytes infusion (dDLI) could induce an improved
      graft-versus-tumor (GVT) effect in patients refractory to standard DLI (stdDLI) for treatment
      of relapse after HSCT.

      dDLI is administered after failure of 1 or several previous stdDLI of at least 107 CD3+
      cells/kg, defined after a minimal follow-up of 2 months after the last injection. The absence
      of previous clinical manifestations of GVHD is required to be included. To prepare dDLI,
      CD25+ Treg are depleted from donor leukaphereses using anti-CD25 magnetic microbeads and a
      CliniMACS device (MYLTENYI). In order to evidence the potential effect of dDLI, the dDLI cell
      dose is adjusted to be below or equal to the maximal cell dose previously received in stdDLI.
      No comparison is planned in the analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of &quot;severe&quot; GHVD (grade &gt;II) following dDLI should be inferior to 40%.</measure>
    <time_frame>4 weeks after dDLI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of GVHD of any grade after dDLI</measure>
    <time_frame>during the 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The anti-tumoral efficiency of dDLI to treat the relapse of the hematological malignancy</measure>
    <time_frame>during the 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The survival and the survival without disease after dDLI</measure>
    <time_frame>during the 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>donor lymphocyte infusion</intervention_name>
    <description>regulatory T cells depletion</description>
    <arm_group_label>1</arm_group_label>
    <other_name>regulatory T cells depletion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematological malignancy except chronic myeloid leukaemia.

          -  Previous allogeneic hematopoietic stem cell transplantation.

          -  Relapse diagnosed at the molecular, cytogenetic, or cytological level.

          -  Failure of a previous stdILD or inclusion in first intention if progressive disease.

          -  Age &gt; 18 years and &lt; 70 years at the time of inclusion.

          -  Performance status considered on the score ECOG &lt; 2.

          -  Life expectation 1-month-old superior.

          -  Signed written informed consent.

          -  Negative HCG in the 7 days preceding the inclusion for women in age of procreation.

          -  Membership of the French national insurance.

        Exclusion Criteria:

          -  Chronic myeloid leukemia

          -  Grade &gt;II acute GVHD or chronic extensive GVHD at the time of inclusion.

          -  Patient receiving an immunosuppressive treatment for GVHD treatment at the time of
             inclusion.

          -  Dysfunction of liver (ALAT/ASAT &gt; 5 N, or bilirubin &gt; 50 µM), or of the renal function
             (creatinine clearance &lt; 30 ml / min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Maury, MD Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cheraï M, Beaumont JL, Azar N, Dhedin N, Sirvent A, Buzyn A, Rubio MT, Vigouroux S, Montagne O, Bories D, Roudot-Thoraval F, Vernant JP, Cordonnier C, Klatzmann D, Cohen JL. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med. 2010 Jul 21;2(41):41ra52. doi: 10.1126/scitranslmed.3001302.</citation>
    <PMID>20650872</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Valérie Millul</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>hematological malignancy</keyword>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>donor lymphocyte infusion</keyword>
  <keyword>antitumor immunotherapy</keyword>
  <keyword>graft-versus-tumor effect</keyword>
  <keyword>regulatory T cells</keyword>
  <keyword>adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

